He still comes to the door when he hears the leash.

That part hasn't changed. The tail still goes. He's still first down the hallway. Whatever else is different, the wanting is completely intact.

It's the second half of the walk that changed. There's a point now — the bench, the corner, the top of the rise — where the pace comes off. He's still walking. He's just not walking the way he was.

And you've quietly rebuilt the walk around it. The short loop instead of the long one. The flat park instead of the hill. Turning for home a little earlier than you used to, before he asks.

Here's the part almost nobody separates: he didn't lose interest. He ran out of runway.

Owners describe it almost the same way every time — mentally he's ready to go, and his body finishes the walk before he's finished wanting it. That gap between what he still wants and what he can spend is the whole thing you're watching.

Which points somewhere specific. Wanting is the brain. Runway is delivery — how well fuel and oxygen actually reach working muscle, and how much energy that muscle can make once they arrive.

That's not the same problem as a stiff joint. And it isn't in the legs.

• You picked the shorter loop, and now the shorter loop is just the walk
• You drive to the flat park instead of the one with the hill
• You turn for home before he asks, because you'd rather not find the limit
• You slow down on the way back without noticing you've done it
• You wait while he stops to sniff something he isn't really smelling
• You've started counting the walk in minutes instead of the loop you used to do
• You already tried a joint supplement, and the walk stayed exactly the same length

If three or more of those landed, read this part slowly — it's the one owners get wrong about themselves.

Stamina isn't one thing. It's a delivery problem and an energy problem stacked on each other, and both drift with age.

Start with delivery. Blood vessels aren't passive tubing. The lining inside is active — it produces a signal, continuously, that keeps the vessel relaxed and flexible so it can widen when a muscle asks for more. Every stride is a fresh request. The lining has to keep answering.

That's the honest version of the analogy: a hose that stiffens makes the pump work harder. Not because the pump got weaker — because the hose stopped helping.

Then energy. Once fuel and oxygen arrive, muscle cells still have to convert them, inside mitochondria — the small power plants packed into every working cell. That machinery is known to change with age [1].

Both halves lean on the same currency. Mitochondria run on a helper molecule called NAD+, and the lining's signalling depends on the same energy supply.

One thing to be straight about first. A walk that got shorter can have causes that have nothing to do with aging, and some are medical conditions that look almost identical from the outside. Those need a vet, not a supplement. If the change came on fast, if he's suddenly winded doing something that used to be easy, or if anything else about him changed at the same time, get him seen first. This article is not a substitute for that visit.

Most owners reading this have already spent money here. A bag of chews. A senior food. Maybe a joint powder or two over a couple of years, each bought with real hope.

And when the walk stayed the same length, somewhere in the back of your mind you decided that was on you. You didn't give it long enough. You bought the cheap one.

Almost none of that is true. There are two simpler explanations, and neither is your judgement.

First: comfort and capacity are different problems. A joint supplement is built to cushion a joint. That's a real job, and for some dogs it's the right one. But a cushioned joint doesn't extend how far a dog can go — it was never designed to. If the walk is ending because he ran out of runway rather than because something hurt, cushioning was never going to move it.

Second: most of what you poured on dinner never got in. Stomach acid, first-pass loss in the liver, ingredients that barely dissolve. The label says one number and the cell gets a much smaller one.

Underneath both sits the same currency. NAD+ is what mitochondria spend to turn food into usable energy, and cells hold less of it as they age. In studies on aging mice, an enzyme called CD38 climbs with age and drives that decline [2]. That part hasn't been studied in dogs yet — and even the size of the decline is still argued over in the research [3].

Pawprint Protocol was built by owners who had already tried the joint route, watched the walk stay the same length, and wanted to know what sat underneath it.

Working with veterinary advisors, they built a daily liquid around one job: give cells the building block they use to make NAD+, and get it there in a form that actually absorbs.

The lead active is NMN — the direct building block for NAD+, and the only active here with published dog research behind it. Oral NMN has been dosed in beagles and came through a safety study cleanly [4]. Be precise about what that study did: the dogs were checked for safety. The NAD+ readings in the same paper came from mice.

There is one properly designed dog trial on this pathway — randomised, placebo-controlled, in senior dogs, where an NAD+ precursor combination moved owner-assessed scores [5]. That was a different product, not this one, so it proves nothing about Pawprint Protocol. What it shows is that the pathway is worth taking seriously in dogs, not only in mice.

Below that sits laboratory work on the vessel lining itself: in mice and cultured cells, NAD+ supported the lining's function [6]. That's early, it isn't a dog, and it's the honest reason this page talks about supporting normal circulation rather than promising anything about it.

Then delivery. Pawprint Protocol is a liposomal liquid, not a pill or a chew — each active wrapped in a tiny fat-based shell so it survives the trip and gets taken up. Built to be absorbed, not just swallowed.

A few drops on whatever he already eats. No pill pockets. No cheese. Individual results may vary.

The senior shelf at any pet store is a wall of one promise: cushion the joint, loosen the stiffness. If that promise had lengthened your walk, you wouldn't be reading this.

Pawprint Protocol works a level below the frame — on the cellular energy that both halves of stamina depend on. A few drops of liquid on his food, once a day.

Four actives, each with a job:

• NMN: The direct building block cells use to make NAD+, the helper molecule mitochondria spend to make energy. This is the hero, and the one with published dog research behind it.
• NAD+: Included as part of the same pathway, supporting the cellular energy system that working muscle draws on all day.
• Resveratrol: A plant compound studied alongside NAD+ for its role in the cell's energy and repair signalling.
• CoQ10: Sits inside the mitochondria, where energy actually gets made. Here it supports muscles and stamina.

All four in a liposomal liquid, because an ingredient that doesn't get absorbed is a line on a label, not a dose.

✔ Supports the cellular energy that stamina is built on
✔ Supports normal circulation and vessel flexibility
✔ Built to be absorbed, not just swallowed
✔ Works alongside any food (kibble, raw, fresh, home-cooked)

Made for dogs 7 and up. Individual results may vary.

You don't have to wait three months to see whether this is doing anything. What owners describe first isn't a dramatic moment — it's the walk quietly stopping getting shorter. Here's the pattern owners tell us about most often, and what the formula is doing underneath it. Individual results may vary.

Nothing dramatic, and that's the point. This stretch is about the dose actually landing: a few drops on dinner, every day, absorbed rather than left in the bowl. What owners tend to report first is at the end of the walk rather than the start — he's a little less flat when he gets home. Individual results may vary.

This is usually where the walk stops getting shorter. Not longer yet — just no longer shrinking, which is the first thing that actually changes direction. Owners often notice they went the old way round without thinking about it, and he was fine.

Owners tend to mention the way home here. Less of the drag on the return leg. Fewer stops that aren't really about sniffing anything. The hill park goes back on the list some days instead of never. Good days stop being events and start being most days.

For most families this is the one they actually notice: they stopped planning the route around him, and they can't say exactly when that stopped.

Three months in, the job changes from noticing to keeping. Cells don't stop aging because you started a bottle, so the dogs who hold their ground are the ones who stay on it.

And it's worth saying plainly: the earlier a dog starts, the more there is to support. Individual results may vary.

A shorter walk isn't the start of this. It's the part you could finally see.

Everything before it — the earlier turn for home, the flat park, the pace coming off at the same corner — was the same thing showing up quietly. He didn't stop wanting the walk. The runway got shorter than the wanting.

That's supportable. And it starts with a few drops on dinner tonight. Individual results may vary.

Reviews are unedited excerpts from verified Trustpilot reviews of Pawprint Lab and describe those owners' own experience, not results on this page's topic.

[1] Chistiakov, D.A. et al. Mitochondrial Aging and Age-Related Dysfunction of Mitochondria. BioMed Research International, 2014. Review. PMID 24818134.

[2] Camacho-Pereira, J. et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction Through an SIRT3-Dependent Mechanism. Cell Metabolism, 2016. Mouse study. PMID 27304511.

[3] Peluso, A. et al. Age-Dependent Decline of NAD+ — Universal Truth or Confounded Consensus? Nutrients, 2022. Review; argues the decline is less established than commonly stated. PMID 35010977.

[4] You, J. et al. Subacute Toxicity Study of Nicotinamide Mononucleotide via Oral Administration. Frontiers in Pharmacology, 2020. Safety study in beagles; the NAD+ measurements in this paper were made in mice, not dogs. PMID 33384603.

[5] Simon, K.E. et al. A Randomized, Controlled Clinical Trial Demonstrates Improved Owner-Assessed Cognitive Function in Senior Dogs Receiving a Senolytic and NAD+ Precursor Combination. Scientific Reports, 2024;14:12399. Dog clinical trial of a different product. PMID 38811634.

[6] Cao, X. et al. Sirtuin 3 Dependent and Independent Effects of NAD+ to Suppress Vascular Inflammation and Improve Endothelial Function in Mice. Antioxidants, 2022;11:706. Mouse and cell-culture study. PMID 35453391.